{"id":"https://openalex.org/W3097838523","doi":"https://doi.org/10.1182/blood-2020-139790","title":"Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas","display_name":"Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3097838523","doi":"https://doi.org/10.1182/blood-2020-139790","mag":"3097838523"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-139790","doi":"https://doi.org/10.1182/blood-2020-139790","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-139790","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101882767","display_name":"Megan L. Lee","orcid":"https://orcid.org/0000-0003-3734-6606","observed_orcids":["https://orcid.org/0000-0003-3734-6606"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Megan Lee","raw_affiliation_strings":["Yale School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060316201","display_name":"Molly Schiffer","orcid":"https://orcid.org/0000-0002-7324-0238","observed_orcids":["https://orcid.org/0000-0002-7324-0238"]},"institutions":[{"id":"https://openalex.org/I1323778983","display_name":"Yale New Haven Hospital","ror":"https://ror.org/05tszed37","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1323778983","https://openalex.org/I4210117499"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Molly Schiffer","raw_affiliation_strings":["Yale-New Haven Hospital, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale-New Haven Hospital, New Haven, CT","institution_ids":["https://openalex.org/I1323778983"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062298311","display_name":"Iris Isufi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Iris Isufi","raw_affiliation_strings":["Hematology, Yale University School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Yale University School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035304428","display_name":"Scott F. Huntington","orcid":"https://orcid.org/0000-0001-7071-6475","observed_orcids":["https://orcid.org/0000-0001-7071-6475"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott F. Huntington","raw_affiliation_strings":["Hematology, Yale University School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Yale University School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071505679","display_name":"Mina L. Xu","orcid":"https://orcid.org/0000-0001-9513-245X","observed_orcids":["https://orcid.org/0000-0001-9513-245X"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mina L. Xu","raw_affiliation_strings":["Department of Pathology and Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology and Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111943699","display_name":"Stuart Seropian","orcid":"https://orcid.org/0000-0001-5168-8325","observed_orcids":["https://orcid.org/0000-0001-5168-8325"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stuart Seropian","raw_affiliation_strings":["Hematology, Yale University School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Yale University School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090669888","display_name":"Lohith Gowda","orcid":"https://orcid.org/0009-0001-1726-9749","observed_orcids":["https://orcid.org/0009-0001-1726-9749"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lohith Gowda","raw_affiliation_strings":["Hematology, Yale University School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Yale University School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069873622","display_name":"Shalin K. Kothari","orcid":"https://orcid.org/0000-0001-9268-0354","observed_orcids":["https://orcid.org/0000-0001-9268-0354"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shalin K. Kothari","raw_affiliation_strings":["Hematology, Yale University School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Yale University School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064358254","display_name":"Michael Girardi","orcid":"https://orcid.org/0000-0003-1887-9343","observed_orcids":["https://orcid.org/0000-0003-1887-9343"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Girardi","raw_affiliation_strings":["Department of Dermatology, Yale University School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Yale University School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5048583088","display_name":"Francine M. Foss","orcid":"https://orcid.org/0000-0001-7843-3162","observed_orcids":["https://orcid.org/0000-0001-7843-3162"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Francine M. Foss","raw_affiliation_strings":["Hematology, Yale Cancer Center, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Yale Cancer Center, New Haven, CT","institution_ids":["https://openalex.org/I2802730090"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.1999,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.55021749,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"21","last_page":"22"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0066999997943639755,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brentuximab-vedotin","display_name":"brentuximab vedotin","score":0.996999979019165},{"id":"https://openalex.org/keywords/once-weekly-dosing","display_name":"weekly dosing","score":0.7900000214576721},{"id":"https://openalex.org/keywords/cd30-expression","display_name":"CD30 expression","score":0.8700000047683716},{"id":"https://openalex.org/keywords/dose-adjustment","display_name":"dose adjustment","score":0.5479999780654907},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.46299999952316284},{"id":"https://openalex.org/keywords/peripheral-t-cell-lymphoma","display_name":"peripheral T-cell lymphoma","score":0.8190000057220459},{"id":"https://openalex.org/keywords/anaplastic-large-cell-lymphoma","display_name":"anaplastic large cell lymphoma","score":0.9169999957084656},{"id":"https://openalex.org/keywords/angioimmunoblastic-t-cell-lymphoma","display_name":"angioimmunoblastic T-cell lymphoma","score":0.972000002861023},{"id":"https://openalex.org/keywords/adult-t-cell-leukemia-lymphoma","display_name":"adult T-cell leukemia/lymphoma","score":0.7919999957084656},{"id":"https://openalex.org/keywords/nk-t-cell-lymphoma","display_name":"NK/T-cell lymphoma","score":0.8980000019073486}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8106033802032471},{"id":"https://openalex.org/C2777756187","wikidata":"https://www.wikidata.org/wiki/Q1891209","display_name":"Mycosis fungoides","level":3,"score":0.7890456914901733},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7055187821388245},{"id":"https://openalex.org/C2778191690","wikidata":"https://www.wikidata.org/wiki/Q422324","display_name":"Brentuximab vedotin","level":4,"score":0.67596435546875},{"id":"https://openalex.org/C2777872185","wikidata":"https://www.wikidata.org/wiki/Q486090","display_name":"Anaplastic large-cell lymphoma","level":3,"score":0.5772230625152588},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5688291788101196},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5302797555923462},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4903373718261719},{"id":"https://openalex.org/C2777589544","wikidata":"https://www.wikidata.org/wiki/Q7667896","display_name":"T-cell lymphoma","level":3,"score":0.46459221839904785},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4447908401489258},{"id":"https://openalex.org/C70905583","wikidata":"https://www.wikidata.org/wiki/Q3648608","display_name":"CD30","level":3,"score":0.30626803636550903},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.24293559789657593}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-139790","doi":"https://doi.org/10.1182/blood-2020-139790","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-139790","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4414371225","https://openalex.org/W2577583147","https://openalex.org/W3166834265","https://openalex.org/W2055342008","https://openalex.org/W2907441236","https://openalex.org/W2119799189","https://openalex.org/W1968119201","https://openalex.org/W2751632119","https://openalex.org/W2549335644","https://openalex.org/W2148342468"],"abstract_inverted_index":{"Introduction":[0],"While":[1],"the":[2,64,101,195,213,227,237,248,284,319,347,364,464],"approved":[3],"dose":[4,29,121,173],"of":[5,30,40,100,108,174,271,302,308,369,377,388,398,457,466,471,618],"brentuximab":[6,169,370,472],"in":[7,43,68,92,197,224,269,274,278,293,300,318,360,382,426,436],"T":[8,79,137,147,152,157,432,489],"cell":[9,80,138,143,148,153,158,163,355,433],"lymphomas":[10,81],"has":[11,424],"been":[12],"every":[13,88,178,187],"3":[14,38,89,115,124,179,186,239,251,258,288,304,321,519],"weeks":[15,116,126,180,259],"on":[16,33,127,418,474,614],"a":[17,28,34,120,128,172,315,353,419,451],"1.8":[18,176,234,372],"mg/kg":[19,32,177,183,235,246,373],"schedule,":[20,396],"earlier":[21],"studies":[22],"exploring":[23],"weekly":[24,35,65,102,122,184,249,263,285,309,328,348,395,420],"dosing":[25,36,66,91,113,329,421],"showed":[26],"that":[27,412],"1.2":[31,182,245],"(every":[37],"out":[39],"4":[41,188,541],"weeks)":[42],"pts":[44,70,94,223,310,323,351,378,427],"with":[45,72,87,168,280,314,327,428,442,450],"Hodgkin's":[46],"lymphoma":[47,139,144,154],"and":[48,77,82,98,117,161,216,242,260,276,286,306,402,423,430,455],"hematologic":[49],"malignancies":[50],"may":[51],"improve":[52],"cancer":[53],"response":[54],"rates":[55],"while":[56],"still":[57],"having":[58],"manageable":[59],"side":[60],"effects3.":[61],"We":[62,105],"explored":[63],"schedule":[67,241,422],"37":[69,118],"(pts)":[71],"mycosis":[73],"fungoides/Sezary":[74],"syndrome":[75],"(MF/SS)":[76],"aggressive":[78,431],"compared":[83,324],"to":[84,95,244,325,404],"our":[85,394],"experience":[86],"week":[90,240,289,305,322],"36":[93,111],"evaluate":[96],"tolerability":[97],"efficacy":[99],"schedule..":[103],"Methods":[104],"reviewed":[106],"charts":[107],"67":[109,222],"pts,":[110,272],"received":[112,119],"q":[114,238,257,287,303,320],"for":[123,236,247,256,262,311,336,343,391],"consecutive":[125],"4-week":[129],"schedule.":[130,252],"Pts":[131,165],"included":[132],"MF/SS":[133,429],"(n=35),":[134],"gamma":[135],"delta":[136],"(n=2),":[140,160],"anaplastic":[141],"large":[142],"(n=12),":[145],"Peripheral":[146],"Lymphoma":[149],"(n=10),":[150],"angioimmunoblastic":[151],"(n=4),":[155],"adult":[156],"leukemia":[159],"NK-T":[162],"lymphoma.":[164],"were":[166,233,254,298,390,440],"treated":[167],"vedotin":[170,371,414,473],"at":[171],"either":[175],"or":[181,205,620],"x":[185,250],"weeks.":[189],"CD30":[190,265,444],"expression":[191,266],"was":[192,210,230,267,341,400],"scored":[193],"by":[194],"pathologist":[196],"tumor":[198],"biopsies":[199],"as":[200,291],"high":[201,268],"(<50%),":[202],"low":[203,273,443],"(5-10%),":[204],"intermediate":[206],"(>10%-49%).":[207],"Toxicity":[208],"data":[209,217,410],"recorded":[211],"from":[212],"medical":[214],"records":[215],"analyzed":[218],"descriptively.":[219],"Results":[220],"Of":[221],"this":[225],"study,":[226],"average":[228],"age":[229],"61.":[231],"Doses":[232],"0.75":[243],"Cycles":[253],"3-47":[255],"1-9.7":[261],"dosing.":[264],"13%":[270],"43%,":[275],"absent":[277],"6%":[279],"equal":[281],"distribution":[282],"between":[283],"cohorts,":[290],"shown":[292],"Table":[294],"1.":[295],"Dose":[296],"adjustments":[297],"made":[299],"67%":[301],"61%":[307],"neurotoxicity":[312,453],"(n=28),":[313],"higher":[316],"incidence":[317,397],"those":[326],"(75%":[330],"vs":[331,339],"53%,":[332],"p=0.01)":[333],".":[334],"Discontinuation":[335],"progression":[337],"(25%":[338],"30%)":[340],"similar":[342],"both":[344],"groups.":[345],"In":[346,363,393],"group,":[349],"8":[350],"had":[352,379],"stem":[354],"transplant,":[356],"including":[357],"allogeneic":[358],"transplantation":[359],"3.":[361],"Conclusion":[362],"Phase":[365],"II":[366],"registration":[367],"trial":[368],"q3":[374],"weeks,":[375],"41%":[376],"neuropathy":[380,399],"(severe":[381],"12%).":[383],"1":[384,477],"Forty":[385],"two":[386],"percent":[387],"discontinuations":[389],"neuropathy.":[392],"lower":[401,469],"led":[403],"fewer":[405],"treatment":[406],"discontinuations.":[407],"Our":[408],"retrospective":[409],"shows":[411],"Brentuximab":[413],"is":[415],"well":[416],"tolerated":[417],"activity":[425],"lymphomas.":[434],"As":[435],"prior":[437],"studies,":[438],"responses":[439],"seen":[441],"expression4,":[445],"5.":[446],"Prospective":[447],"clinical":[448],"trials":[449],"self-reported":[452],"scale":[454],"quality":[456],"life":[458],"instruments":[459],"should":[460],"be":[461],"performed":[462],"address":[463],"impact":[465],"more":[467],"frequent,":[468],"doses":[470],"patient":[475],"outcomes.":[476],"Pro":[478],"B,":[479],"Advani":[480,526],"R,":[481,507],"Brice":[482],"P,":[483,547],"Bartlett":[484],"NL,":[485],"Rosenblatt":[486,524],"JD,":[487,525],"Illidge":[488],"et":[490,512,532,575],"al.J":[491,576],"Clin":[492,555,577],"Oncol":[493,556,578],"2012;":[494,536],"30(18):":[495],"2190-2196.":[496],"doi:":[497,517,539,560,582],"10.1200/JCO.2011.38.0402":[498],"2":[499],"Prince":[500],"HM,":[501],"Kim":[502,563],"YH,":[503,564],"Horwitz":[504],"SM,":[505],"Dummer":[506],"Scarisbrick":[508],"J,":[509],"Quaglino":[510],"P":[511],"al.Lancet":[513],"2017;":[514],"390(10094):":[515],"555-566.":[516],"10.1016/S0140-6736(17)31266-7":[518],"Fanale":[520],"MA,":[521],"Forero-Torres":[522],"A,":[523],"RH,":[527],"Franklin":[528],"AR,":[529],"Kennedy":[530],"DA":[531],"al.Clin":[533],"Cancer":[534],"Res":[535],"18(1):":[537],"248-255.":[538],"10.1158/1078-0432.CCR-11-1425":[540],"Duvic":[542],"M,":[543,566],"Tetzlaff":[544],"MT,":[545],"Gangar":[546],"Clos":[548],"AL,":[549],"Sui":[550],"D,":[551],"Talpur":[552],"R.":[553],"J":[554],"2015;":[557,579],"33(32):":[558,580],"3759-3765.":[559],"10.1200/JCO.2014.60.3787":[561],"5":[562],"Tavallaee":[565],"Sundram":[567],"U,":[568],"Salva":[569],"KA,":[570],"Wood":[571],"GS,":[572],"Li":[573],"S":[574],"3750-3758.":[581],"10.1200/JCO.2014.60.3969":[583],"Figure":[584],"Disclosures":[585],"Huntington:":[586],"Pharmacyclics:":[587],"Honoraria;":[588,606],"DTRM:":[589],"Research":[590,598,602],"Funding;":[591,599,603],"Genentech:":[592],"Consultancy;":[593,595,608],"Novartis:":[594],"Celgene:":[596],"Consultancy,":[597,605],"TG":[600],"Therapeutics:":[601],"Bayer:":[604],"AbbVie:":[607],"Astrazeneca:":[609],"Honoraria.":[610],"Xu:Seattle":[611],"Genetics:":[612],"Membership":[613],"an":[615],"entity's":[616],"Board":[617],"Directors":[619],"advisory":[621],"committees.":[622]},"counts_by_year":[{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-11-09T00:00:00"}